nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiludronate—PTPN1—myometrium—uterine cancer	0.0342	0.0861	CbGeAlD
Tiludronate—PTPN1—Regulation of IFNG signaling—SOCS3—uterine cancer	0.0266	0.0661	CbGpPWpGaD
Tiludronate—PTPN1—uterine cervix—uterine cancer	0.0266	0.067	CbGeAlD
Tiludronate—PTPN1—decidua—uterine cancer	0.0253	0.0638	CbGeAlD
Tiludronate—PTPN1—renal system—uterine cancer	0.0249	0.0627	CbGeAlD
Tiludronate—PTPN1—endometrium—uterine cancer	0.024	0.0606	CbGeAlD
Tiludronate—PTPN1—mammalian vulva—uterine cancer	0.0233	0.0586	CbGeAlD
Tiludronate—PTPN1—uterus—uterine cancer	0.0221	0.0558	CbGeAlD
Tiludronate—ATP6V1A—myometrium—uterine cancer	0.0205	0.0516	CbGeAlD
Tiludronate—Developmental delay—Medroxyprogesterone Acetate—uterine cancer	0.0201	0.0997	CcSEcCtD
Tiludronate—Congenital anomaly—Medroxyprogesterone Acetate—uterine cancer	0.0201	0.0997	CcSEcCtD
Tiludronate—PTPN1—female reproductive system—uterine cancer	0.0199	0.0502	CbGeAlD
Tiludronate—PTPN1—IGF1 pathway—YWHAE—uterine cancer	0.0184	0.0458	CbGpPWpGaD
Tiludronate—PTPN1—female gonad—uterine cancer	0.0181	0.0457	CbGeAlD
Tiludronate—PTPN1—vagina—uterine cancer	0.018	0.0454	CbGeAlD
Tiludronate—PTPN1—Growth hormone receptor signaling—SOCS3—uterine cancer	0.0173	0.043	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNA signaling—SOCS3—uterine cancer	0.0162	0.0403	CbGpPWpGaD
Tiludronate—ATP6V1A—uterine cervix—uterine cancer	0.0159	0.0401	CbGeAlD
Tiludronate—ATP6V1A—decidua—uterine cancer	0.0152	0.0382	CbGeAlD
Tiludronate—ATP6V1A—renal system—uterine cancer	0.0149	0.0376	CbGeAlD
Tiludronate—ATP6V1A—endometrium—uterine cancer	0.0144	0.0363	CbGeAlD
Tiludronate—ATP6V1A—mammalian vulva—uterine cancer	0.0139	0.0351	CbGeAlD
Tiludronate—PTPN1—IGF1 pathway—IGF1R—uterine cancer	0.0134	0.0334	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—MAP3K4—uterine cancer	0.0134	0.0333	CbGpPWpGaD
Tiludronate—ATP6V1A—uterus—uterine cancer	0.0133	0.0335	CbGeAlD
Tiludronate—ATP6V1A—female reproductive system—uterine cancer	0.0119	0.0301	CbGeAlD
Tiludronate—Influenza-like symptoms—Progesterone—uterine cancer	0.0118	0.0586	CcSEcCtD
Tiludronate—PTPN1—lymph node—uterine cancer	0.0116	0.0294	CbGeAlD
Tiludronate—ATP6V1A—female gonad—uterine cancer	0.0109	0.0274	CbGeAlD
Tiludronate—ATP6V1A—vagina—uterine cancer	0.0108	0.0272	CbGeAlD
Tiludronate—PTPN1—Interferon alpha/beta signaling—IRF1—uterine cancer	0.0106	0.0264	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—IRF1—uterine cancer	0.0101	0.0252	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—SOCS3—uterine cancer	0.00931	0.0231	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—IGF1R—uterine cancer	0.00922	0.0229	CbGpPWpGaD
Tiludronate—Bone pain—Progesterone—uterine cancer	0.00879	0.0437	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—MET—uterine cancer	0.00822	0.0204	CbGpPWpGaD
Tiludronate—Influenza like illness—Progesterone—uterine cancer	0.00818	0.0406	CcSEcCtD
Tiludronate—PTPN1—Interferon alpha/beta signaling—SOCS3—uterine cancer	0.00778	0.0194	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—SOCS3—uterine cancer	0.00742	0.0185	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—MET—uterine cancer	0.00711	0.0177	CbGpPWpGaD
Tiludronate—ATP6V1A—lymph node—uterine cancer	0.00698	0.0176	CbGeAlD
Tiludronate—PTPN1—Leptin signaling pathway—SOCS3—uterine cancer	0.00694	0.0173	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—CDH1—uterine cancer	0.00616	0.0153	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—YWHAE—uterine cancer	0.00588	0.0146	CbGpPWpGaD
Tiludronate—PTPN1—N-cadherin signaling events—CTNNB1—uterine cancer	0.00572	0.0142	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—STK11—uterine cancer	0.00523	0.013	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—ESR1—uterine cancer	0.00495	0.0123	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—IRF1—uterine cancer	0.00494	0.0123	CbGpPWpGaD
Tiludronate—Pain—Carboplatin—uterine cancer	0.00489	0.0243	CcSEcCtD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	0.00477	0.0119	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—uterine cancer	0.00472	0.0117	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—VEGFA—uterine cancer	0.00463	0.0115	CbGpPWpGaD
Tiludronate—PTPN1—IGF1 pathway—PIK3CA—uterine cancer	0.00455	0.0113	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—CTNNB1—uterine cancer	0.00454	0.0113	CbGpPWpGaD
Tiludronate—Rhinitis—Progesterone—uterine cancer	0.00424	0.0211	CcSEcCtD
Tiludronate—PTPN1—IGF1 pathway—HRAS—uterine cancer	0.00421	0.0105	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—uterine cancer	0.00409	0.0102	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—FGFR2—uterine cancer	0.00408	0.0102	CbGpPWpGaD
Tiludronate—PTPN1—Integrin alphaIIb beta3 signaling—AKT1—uterine cancer	0.00404	0.0101	CbGpPWpGaD
Tiludronate—PTPN1—N-cadherin signaling events—PIK3CA—uterine cancer	0.00393	0.00978	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—SOCS3—uterine cancer	0.00379	0.00942	CbGpPWpGaD
Tiludronate—PTPN1—IGF1 pathway—AKT1—uterine cancer	0.00372	0.00925	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—ERBB2—uterine cancer	0.00363	0.00904	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—SOCS3—uterine cancer	0.00362	0.00901	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—PIK3CA—uterine cancer	0.00362	0.00899	CbGpPWpGaD
Tiludronate—Back pain—Progesterone—uterine cancer	0.00356	0.0177	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—IGF1R—uterine cancer	0.00352	0.00876	CbGpPWpGaD
Tiludronate—Vertigo—Progesterone—uterine cancer	0.00331	0.0164	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IRF1—uterine cancer	0.0033	0.00821	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Pathway—PIK3CA—uterine cancer	0.00329	0.00818	CbGpPWpGaD
Tiludronate—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00323	0.016	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00317	0.00787	CbGpPWpGaD
Tiludronate—PTPN1—Platelet Aggregation (Plug Formation)—AKT1—uterine cancer	0.00314	0.00782	CbGpPWpGaD
Tiludronate—Arthralgia—Progesterone—uterine cancer	0.00313	0.0156	CcSEcCtD
Tiludronate—Myalgia—Progesterone—uterine cancer	0.00313	0.0156	CcSEcCtD
Tiludronate—PTPN1—Insulin Pathway—HRAS—uterine cancer	0.00304	0.00757	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—uterine cancer	0.00302	0.00751	CbGpPWpGaD
Tiludronate—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.003	0.0149	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—PIK3CA—uterine cancer	0.00293	0.00729	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—uterine cancer	0.00289	0.00719	CbGpPWpGaD
Tiludronate—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.00284	0.0141	CcSEcCtD
Tiludronate—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00284	0.0141	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00274	0.0136	CcSEcCtD
Tiludronate—PTPN1—Insulin Pathway—AKT1—uterine cancer	0.00269	0.00668	CbGpPWpGaD
Tiludronate—Dyspepsia—Progesterone—uterine cancer	0.00264	0.0131	CcSEcCtD
Tiludronate—Pain—Progesterone—uterine cancer	0.00257	0.0128	CcSEcCtD
Tiludronate—Bone pain—Epirubicin—uterine cancer	0.00252	0.0125	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00248	0.0123	CcSEcCtD
Tiludronate—Gastrointestinal pain—Progesterone—uterine cancer	0.00246	0.0122	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—SOCS3—uterine cancer	0.00242	0.00602	CbGpPWpGaD
Tiludronate—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.0024	0.0119	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—AKT1—uterine cancer	0.00239	0.00595	CbGpPWpGaD
Tiludronate—Abdominal pain—Progesterone—uterine cancer	0.00237	0.0118	CcSEcCtD
Tiludronate—Influenza like illness—Epirubicin—uterine cancer	0.00234	0.0116	CcSEcCtD
Tiludronate—Bone pain—Doxorubicin—uterine cancer	0.00233	0.0116	CcSEcCtD
Tiludronate—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.0111	CcSEcCtD
Tiludronate—Myalgia—Dactinomycin—uterine cancer	0.00221	0.011	CcSEcCtD
Tiludronate—Influenza like illness—Doxorubicin—uterine cancer	0.00217	0.0108	CcSEcCtD
Tiludronate—Asthenia—Progesterone—uterine cancer	0.00215	0.0107	CcSEcCtD
Tiludronate—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.0107	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—PIK3CA—uterine cancer	0.00208	0.00516	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—PTEN—uterine cancer	0.00206	0.00512	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—IRF1—uterine cancer	0.00206	0.00511	CbGpPWpGaD
Tiludronate—Diarrhoea—Progesterone—uterine cancer	0.00206	0.0102	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—HRAS—uterine cancer	0.00202	0.00503	CbGpPWpGaD
Tiludronate—Dizziness—Progesterone—uterine cancer	0.00199	0.00987	CcSEcCtD
Tiludronate—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00195	0.0097	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—NRAS—uterine cancer	0.00195	0.00485	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00193	0.00961	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—uterine cancer	0.00192	0.00478	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—AKR1B10—uterine cancer	0.0019	0.00474	CbGpPWpGaD
Tiludronate—Headache—Progesterone—uterine cancer	0.00188	0.00935	CcSEcCtD
Tiludronate—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00186	0.00925	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—NRAS—uterine cancer	0.00184	0.00457	CbGpPWpGaD
Tiludronate—Back pain—Etoposide—uterine cancer	0.00182	0.00905	CcSEcCtD
Tiludronate—Pain—Dactinomycin—uterine cancer	0.00182	0.00902	CcSEcCtD
Tiludronate—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.0018	0.00894	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—AKT1—uterine cancer	0.00179	0.00444	CbGpPWpGaD
Tiludronate—Nausea—Progesterone—uterine cancer	0.00178	0.00886	CcSEcCtD
Tiludronate—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00174	0.00862	CcSEcCtD
Tiludronate—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00171	0.00847	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—uterine cancer	0.0017	0.00422	CbGpPWpGaD
Tiludronate—Vertigo—Etoposide—uterine cancer	0.00169	0.0084	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—PTEN—uterine cancer	0.00169	0.0042	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—KRAS—uterine cancer	0.00168	0.00418	CbGpPWpGaD
Tiludronate—Abdominal pain—Dactinomycin—uterine cancer	0.00168	0.00834	CcSEcCtD
Tiludronate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00803	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—KRAS—uterine cancer	0.00158	0.00393	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—RNF43—uterine cancer	0.00158	0.00392	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—uterine cancer	0.00154	0.00384	CbGpPWpGaD
Tiludronate—Asthenia—Dactinomycin—uterine cancer	0.00152	0.00757	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—PIK3CA—uterine cancer	0.00145	0.00361	CbGpPWpGaD
Tiludronate—Diarrhoea—Dactinomycin—uterine cancer	0.00145	0.00722	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—HRAS—uterine cancer	0.00143	0.00355	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—HRAS—uterine cancer	0.00134	0.00334	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—AKR1B10—uterine cancer	0.00133	0.00332	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKR1B10—uterine cancer	0.00133	0.00332	CbGpPWpGaD
Tiludronate—Pain—Etoposide—uterine cancer	0.00131	0.00653	CcSEcCtD
Tiludronate—ATP6V1A—Disease—AKR1C1—uterine cancer	0.0013	0.00323	CbGpPWpGaD
Tiludronate—Nausea—Dactinomycin—uterine cancer	0.00126	0.00626	CcSEcCtD
Tiludronate—Gastrointestinal pain—Etoposide—uterine cancer	0.00126	0.00624	CcSEcCtD
Tiludronate—Rhinitis—Epirubicin—uterine cancer	0.00122	0.00604	CcSEcCtD
Tiludronate—Abdominal pain—Etoposide—uterine cancer	0.00121	0.00603	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—PIK3CA—uterine cancer	0.00119	0.00297	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.00118	0.00293	CbGpPWpGaD
Tiludronate—Rhinitis—Doxorubicin—uterine cancer	0.00112	0.00559	CcSEcCtD
Tiludronate—ATP6V1A—Disease—DCN—uterine cancer	0.00112	0.0028	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—RNF43—uterine cancer	0.00111	0.00275	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—RNF43—uterine cancer	0.00111	0.00275	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—HRAS—uterine cancer	0.0011	0.00274	CbGpPWpGaD
Tiludronate—Asthenia—Etoposide—uterine cancer	0.0011	0.00548	CcSEcCtD
Tiludronate—PTPN1—Immune System—IRF1—uterine cancer	0.00108	0.00268	CbGpPWpGaD
Tiludronate—Diarrhoea—Etoposide—uterine cancer	0.00105	0.00522	CcSEcCtD
Tiludronate—Back pain—Epirubicin—uterine cancer	0.00102	0.00507	CcSEcCtD
Tiludronate—Dizziness—Etoposide—uterine cancer	0.00102	0.00505	CcSEcCtD
Tiludronate—PTPN1—Signaling Pathways—INHBA—uterine cancer	0.00101	0.00251	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—INHBA—uterine cancer	0.00101	0.00251	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—AKR1C3—uterine cancer	0.001	0.00249	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—HMGA1—uterine cancer	0.000975	0.00242	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—AKT1—uterine cancer	0.000974	0.00242	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—FBXW7—uterine cancer	0.000966	0.0024	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—NRAS—uterine cancer	0.000964	0.0024	CbGpPWpGaD
Tiludronate—Headache—Etoposide—uterine cancer	0.000963	0.00478	CcSEcCtD
Tiludronate—Vertigo—Epirubicin—uterine cancer	0.000948	0.00471	CcSEcCtD
Tiludronate—Back pain—Doxorubicin—uterine cancer	0.000945	0.00469	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	0.000921	0.00229	CbGpPWpGaD
Tiludronate—Nausea—Etoposide—uterine cancer	0.000913	0.00453	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—AKR1C1—uterine cancer	0.00091	0.00226	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKR1C1—uterine cancer	0.00091	0.00226	CbGpPWpGaD
Tiludronate—Myalgia—Epirubicin—uterine cancer	0.000898	0.00446	CcSEcCtD
Tiludronate—Arthralgia—Epirubicin—uterine cancer	0.000898	0.00446	CcSEcCtD
Tiludronate—ATP6V1A—Disease—FBXW7—uterine cancer	0.000892	0.00222	CbGpPWpGaD
Tiludronate—Vertigo—Doxorubicin—uterine cancer	0.000877	0.00436	CcSEcCtD
Tiludronate—Arthralgia—Doxorubicin—uterine cancer	0.000831	0.00413	CcSEcCtD
Tiludronate—Myalgia—Doxorubicin—uterine cancer	0.000831	0.00413	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—KRAS—uterine cancer	0.00083	0.00206	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—SOCS3—uterine cancer	0.00079	0.00197	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000785	0.0039	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	0.000762	0.0019	CbGpPWpGaD
Tiludronate—Dyspepsia—Epirubicin—uterine cancer	0.000758	0.00377	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—AKT1—uterine cancer	0.000752	0.00187	CbGpPWpGaD
Tiludronate—Pain—Epirubicin—uterine cancer	0.000737	0.00366	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000726	0.00361	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HRAS—uterine cancer	0.000705	0.00175	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000704	0.0035	CcSEcCtD
Tiludronate—Dyspepsia—Doxorubicin—uterine cancer	0.000701	0.00349	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—AKR1C3—uterine cancer	0.000701	0.00174	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKR1C3—uterine cancer	0.000701	0.00174	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CDKN2B—uterine cancer	0.000699	0.00174	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PGR—uterine cancer	0.000683	0.0017	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PGR—uterine cancer	0.000683	0.0017	CbGpPWpGaD
Tiludronate—Pain—Doxorubicin—uterine cancer	0.000681	0.00339	CcSEcCtD
Tiludronate—Abdominal pain—Epirubicin—uterine cancer	0.000681	0.00338	CcSEcCtD
Tiludronate—PTPN1—Immune System—FGFR2—uterine cancer	0.000659	0.00164	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000652	0.00324	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—YWHAE—uterine cancer	0.000651	0.00162	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—YWHAE—uterine cancer	0.000651	0.00162	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—EP300—uterine cancer	0.000642	0.0016	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—SMAD3—uterine cancer	0.000638	0.00159	CbGpPWpGaD
Tiludronate—Abdominal pain—Doxorubicin—uterine cancer	0.00063	0.00313	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—FBXW7—uterine cancer	0.000624	0.00155	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—FBXW7—uterine cancer	0.000624	0.00155	CbGpPWpGaD
Tiludronate—Asthenia—Epirubicin—uterine cancer	0.000618	0.00307	CcSEcCtD
Tiludronate—ATP6V1A—Disease—FGFR2—uterine cancer	0.000608	0.00151	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—VEGFA—uterine cancer	0.000608	0.00151	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—NRAS—uterine cancer	0.0006	0.00149	CbGpPWpGaD
Tiludronate—Diarrhoea—Epirubicin—uterine cancer	0.000589	0.00293	CcSEcCtD
Tiludronate—ATP6V1A—Disease—MTHFR—uterine cancer	0.000586	0.00146	CbGpPWpGaD
Tiludronate—Asthenia—Doxorubicin—uterine cancer	0.000572	0.00284	CcSEcCtD
Tiludronate—Dizziness—Epirubicin—uterine cancer	0.00057	0.00283	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—STK11—uterine cancer	0.000546	0.00136	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—STK11—uterine cancer	0.000546	0.00136	CbGpPWpGaD
Tiludronate—Diarrhoea—Doxorubicin—uterine cancer	0.000545	0.00271	CcSEcCtD
Tiludronate—Headache—Epirubicin—uterine cancer	0.00054	0.00268	CcSEcCtD
Tiludronate—Dizziness—Doxorubicin—uterine cancer	0.000527	0.00262	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—KRAS—uterine cancer	0.000517	0.00129	CbGpPWpGaD
Tiludronate—Nausea—Epirubicin—uterine cancer	0.000512	0.00254	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—SOCS3—uterine cancer	0.000511	0.00127	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—SOCS3—uterine cancer	0.000511	0.00127	CbGpPWpGaD
Tiludronate—Headache—Doxorubicin—uterine cancer	0.000499	0.00248	CcSEcCtD
Tiludronate—PTPN1—Immune System—CDH1—uterine cancer	0.000491	0.00122	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CDKN2B—uterine cancer	0.000489	0.00122	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CDKN2B—uterine cancer	0.000489	0.00122	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—IGF1R—uterine cancer	0.000475	0.00118	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—IGF1R—uterine cancer	0.000475	0.00118	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—PIK3CA—uterine cancer	0.000475	0.00118	CbGpPWpGaD
Tiludronate—Nausea—Doxorubicin—uterine cancer	0.000473	0.00235	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—TP53—uterine cancer	0.000459	0.00114	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—SMAD3—uterine cancer	0.000447	0.00111	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—SMAD3—uterine cancer	0.000447	0.00111	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—HRAS—uterine cancer	0.000439	0.00109	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—FGFR2—uterine cancer	0.000426	0.00106	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—FGFR2—uterine cancer	0.000426	0.00106	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—ERBB2—uterine cancer	0.000414	0.00103	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—AKT1—uterine cancer	0.000388	0.000965	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CDKN1B—uterine cancer	0.000383	0.000953	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—ERBB2—uterine cancer	0.000382	0.00095	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—ESR1—uterine cancer	0.000365	0.000907	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ESR1—uterine cancer	0.000365	0.000907	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CTNNB1—uterine cancer	0.000362	0.0009	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CDKN1B—uterine cancer	0.000354	0.00088	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PTEN—uterine cancer	0.000353	0.000878	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—EP300—uterine cancer	0.000337	0.000837	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CTNNB1—uterine cancer	0.000334	0.000831	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PTEN—uterine cancer	0.000326	0.00081	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CCL2—uterine cancer	0.000321	0.000798	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CCL2—uterine cancer	0.000321	0.000798	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—NRAS—uterine cancer	0.000315	0.000783	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—EP300—uterine cancer	0.000311	0.000773	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—NRAS—uterine cancer	0.000291	0.000723	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—KRAS—uterine cancer	0.000271	0.000674	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—ERBB2—uterine cancer	0.000268	0.000665	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ERBB2—uterine cancer	0.000268	0.000665	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CXCL8—uterine cancer	0.000254	0.000631	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CXCL8—uterine cancer	0.000254	0.000631	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—KRAS—uterine cancer	0.00025	0.000622	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PIK3CA—uterine cancer	0.000249	0.000619	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CDKN1B—uterine cancer	0.000248	0.000616	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CDKN1B—uterine cancer	0.000248	0.000616	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CTNNB1—uterine cancer	0.000234	0.000582	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CTNNB1—uterine cancer	0.000234	0.000582	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—HRAS—uterine cancer	0.00023	0.000573	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PIK3CA—uterine cancer	0.00023	0.000572	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PTEN—uterine cancer	0.000228	0.000567	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PTEN—uterine cancer	0.000228	0.000567	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—EP300—uterine cancer	0.000218	0.000541	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—EP300—uterine cancer	0.000218	0.000541	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—HRAS—uterine cancer	0.000213	0.000529	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—VEGFA—uterine cancer	0.000206	0.000513	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—VEGFA—uterine cancer	0.000206	0.000513	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—NRAS—uterine cancer	0.000204	0.000506	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NRAS—uterine cancer	0.000204	0.000506	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—AKT1—uterine cancer	0.000203	0.000506	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—AKT1—uterine cancer	0.000188	0.000467	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—KRAS—uterine cancer	0.000175	0.000436	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—KRAS—uterine cancer	0.000175	0.000436	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—PIK3CA—uterine cancer	0.000161	0.0004	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PIK3CA—uterine cancer	0.000161	0.0004	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TP53—uterine cancer	0.000156	0.000387	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TP53—uterine cancer	0.000156	0.000387	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—HRAS—uterine cancer	0.000149	0.00037	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—HRAS—uterine cancer	0.000149	0.00037	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—AKT1—uterine cancer	0.000131	0.000327	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKT1—uterine cancer	0.000131	0.000327	CbGpPWpGaD
